Shares of Synthetic Biologics Inc (NYSEMKT:SYN) have received an average recommendation of “Buy” from the eight research firms that are covering the company, MarketBeat.com reports. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and five have given a buy rating to the company. The average 12-month target price among brokers that have issued ratings on the stock in the last year is $4.51.
SYN has been the topic of a number of recent analyst reports. Zacks Investment Research downgraded shares of Synthetic Biologics from a “hold” rating to a “sell” rating in a report on Thursday, May 4th. William Blair reaffirmed an “outperform” rating and set a $5.00 price objective on shares of Synthetic Biologics in a research report on Monday, May 22nd. Finally, ValuEngine cut shares of Synthetic Biologics from a “sell” rating to a “strong sell” rating in a research report on Friday, June 2nd.
Shares of Synthetic Biologics (NYSEMKT:SYN) opened at 0.5472 on Monday. The firm has a 50-day moving average of $0.56 and a 200 day moving average of $0.64. Synthetic Biologics has a 1-year low of $0.41 and a 1-year high of $1.90. The stock’s market capitalization is $66.70 million.
Synthetic Biologics (NYSEMKT:SYN) last issued its earnings results on Thursday, August 3rd. The company reported ($0.03) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.06) by $0.03. On average, equities analysts anticipate that Synthetic Biologics will post ($0.21) earnings per share for the current fiscal year.
Large investors have recently made changes to their positions in the stock. Creative Planning boosted its stake in shares of Synthetic Biologics by 65.4% in the second quarter. Creative Planning now owns 177,000 shares of the company’s stock worth $100,000 after buying an additional 70,000 shares during the last quarter. UBS Group AG boosted its stake in shares of Synthetic Biologics by 10.3% in the first quarter. UBS Group AG now owns 214,357 shares of the company’s stock worth $135,000 after buying an additional 20,038 shares during the last quarter. Bank of New York Mellon Corp boosted its stake in shares of Synthetic Biologics by 3.1% in the first quarter. Bank of New York Mellon Corp now owns 263,598 shares of the company’s stock worth $166,000 after buying an additional 7,962 shares during the last quarter. LMR Partners LLP acquired a new stake in shares of Synthetic Biologics during the second quarter worth about $194,000. Finally, Norges Bank acquired a new stake in shares of Synthetic Biologics during the fourth quarter worth about $356,000.
Synthetic Biologics Company Profile
Synthetic Biologics, Inc is a clinical-stage company. The Company is engaged in developing therapeutics to protect the gut microbiome while targeting pathogen-specific diseases. The Company’s lead product candidates in Phase II development are SYN-010, which is intended to reduce the impact of methane-producing organisms in the gut microbiome to treat an underlying cause of irritable bowel syndrome with constipation (IBS-C), and SYN-004, which is designed to protect the gut microbiome (gastrointestinal (GI) microflora) from the effects of certain commonly used intravenous (IV) antibiotics for the prevention of C.
Receive News & Ratings for Synthetic Biologics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Synthetic Biologics Inc and related companies with MarketBeat.com's FREE daily email newsletter.